Page 5 - Alnylam News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alnylam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alnylam Today - Breaking & Trending Today

Alnylam Announces Pricing Of $900 Mln Convertible Senior Notes Offering

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY), a RNAi therapeutics company, on Tuesday announced the pricing of its previously announced private offering of $900 million of 1 percent ....

United States , Alnylam Pharmaceuticals Inc , Nasdaq Global Select Market ,

Alnylam Presents Positive Results From Phase 3 Study Of Patisiran In ATTR Amyloidosis

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment ....

United States , Alnylam Pharmaceuticals Inc , More Such Health News , Minute Walk Test ,

Alnylam Pharmaceuticals, Inc.: Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

-Treatment with Cemdisiran Resulted in a Higher Proportion of Patients Achieving Clinically Meaningful Reductions in 24-Hour Urine Protein to Creatinine Ratio, as Compared to Patients on Placebo - ....

United Kingdom , Christine Regan Lindenboom , Josh Brodsky , Sonalee Agarwal , Regeneron Pharmaceuticals , Alnylam Pharmaceuticals Inc , Exchange Commission , Alnylam Pharmaceuticals , Program Leader For The Cemdisiran , Cemdisiran Resulted , Higher Proportion , Hour Urine Protein , Creatinine Ratio , Proteinuria Reduction Seen , Secondary Endpoints , Was Generally Well Tolerated , Iga Nephropathy , European Meeting , Human Disease , Vice President , Program Leader , Enhanced Stabilization Chemistry , Nobel Prize Winning , Forward Looking Statements , Private Securities Litigation Reform Act , Quarterly Report ,

Alnylam: Phase 3 Study Of Patisiran In ATTR Amyloidosis With Cardiomyopathy Meets Main Goal

PARIS (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) said that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated ....

France General , Drug Administration , Alnylam Pharmaceuticals Inc , More Such Health News , Minute Walk Test , Kansas City Cardiomyopathy ,

Alnylam Q2 Loss Widens, SGEN Boosts Revenue Outlook, NVCR To Report LUNAR Study Data In Q1

AMSTERDAM (dpa-AFX) - The following are some of the healthcare companies that reported quarterly financial results and provided an update on their pipeline progress on Thursday.1. ALNY Q2 Loss ....

Noord Holland , Thomson Reuters , European Commission , Ekso Bionics Holdings Inc , Alnylam Pharmaceuticals Inc , Cvrx Inc , Seagen Inc , Revenue Miss , Myasthenia Gravis , Biologics License Application , Bionics Holdings , Multiple Sclerosis ,